Scroll To Top

Is There a New Superdrug on the Way?

Is There a New Superdrug on the Way?


In summer 2006 the Food and Drug Administration approved Atripla, the first single-pill treatment containing a full three-drug antiretroviral regimen. While a boon to many, the Sustiva component of the combo pill kept it from a sizable number of HIVers, including pregnant women, people unable to handle Sustiva's central nervous system side effects, and African-Americans, who have been shown in studies to metabolize Sustiva too slowly. Now drugmaker Gilead Sciences is planning clinical trials of a Sustiva-free alternative: Quad, a four-in-one combination pill some have already dubbed an anti-HIV 'superdrug.' Quad combines Gilead's nucleoside analogs Emtriva and Viread with the company's experimental integrase inhibitor, elvitegravir, and a booster medication. 'If Sustiva isn't useful, Quad may be of more benefit,' Gilead president John Milligan said of the new four-in-one pill. The company hopes to begin safety trials of Quad in the second half of the year.

Out Subscription Lil Nas XAdvocateChannel promotion

From our Sponsors

Most Popular

Fifth Person Cured of HIV

Latest Stories